Presentation - CU Cancer Center

Karen Knudsen, PhD Executive Vice President of Oncology Services Jefferson Health

Reporting from the 2021 Genitourinary Cancers Symposium, Karen Knudsen comments on results from CRPC studies looking at molecular determinants associated with long term response to apalutamide in the SPARTAN study, and the final results from the ACIS study testing the addition of apalutamide to abiraterone and prednisone in metastatic disease.

She also gives an overview of the final results from the TITAN study testing apalutamide in metastatic castration-sensitive setting receiving ADT.